Mucormycosis in COVID-19: modifiable risk factors and its mitigation in India


  • Sherin Mary Shaji Department of Pharmacy Practice, JSS College of Pharmacy, JSS Academy of Higher Education & Research, Ooty, Nilgiris, Tamil Nadu, India
  • Sadagoban Gopal Krishnamoorthy Department of Pharmacy Practice, JSS College of Pharmacy, JSS Academy of Higher Education & Research, Ooty, Nilgiris, Tamil Nadu, India
  • Swathi Swaroopa Borra Department of Pharmacy Practice, JSS College of Pharmacy, JSS Academy of Higher Education & Research, Ooty, Nilgiris, Tamil Nadu, India



Mucormycosis, COVID-19, Risk factors, Mycology


While combating the second wave of COVID-19, India has now been afflicted by another epidemic caused by mucormycosis, a life-threatening opportunistic infection. Due to their immune-suppressed status, COVID-19 patients in India are now more likely to develop mucormycosis during or after treatment. Uncontrolled diabetes, irrational use of steroids, as well as the severity of COVID-19 can all contribute to the growth of mucormycosis. Risk mitigation strategies that could be used to control the rise of mucormycosis-related COVID-19 patients should be evaluated. The purpose of this article is to explore the modifiable risk variables that are involved in the medical management of COVID-19 patients, as well as the mechanisms through which they raise the risk. This overview also includes a brief discussion of mycology and how the disease pattern varies depending on the regions of the body affected. In this article, we detailed about the early detection and treatment of mucormycosis in COVID-19 patients.


Aranjani JM, Manuel A, Razack AHI, Mathew ST (2021) COVID-19-associated mucormycosis: evidence-based critical review of an emerging infection burden during the pandemic's second wave in India. PLoS Neglected Tropical Diseases 15(11):e0009921.

Barshes N, Goodpastor SE, Goss J (2004). Pharmacologic immunosuppression. Frontiers in Bioscience 9(1):411–420.

Bitar D, Lortholary O, Le Strat Y, Nicolau J, Coignard B, Tattevin P, Che D, Dromer F (2014) Population-based analysis of invasive fungal infections, France, 2001-2010. Emerging infectious diseases 20(7):1163–1169.

Bitar D, Van Cauteren D, Lanternier F, Dannaoui E, Che D, Dromer F, Desenclos JC, Lortholary O (2009) Increasing incidence of zygomycosis (mucormycosis), France, 1997-2006. Emerging infectious diseases 15(9):1395–1401.

CDC - Centers for Disease Control and Prevention. (2022) Treatment for Mucormycosis. Mucormycosis. Fungal Diseases.| Available from: [Accessed 30 June 2021].

Cornely OA, Alastruey-Izquierdo A, Arenz D, Chen SCA, Dannaoui E, Hochhegger B, Hoenigl M, Jensen HE, Lagrou K, Lewis RE, Mellinghoff SC, Mer M, Pana ZD, Seidel D, Sheppard DC, Wahba R, Akova M, Alanio A, Al-Hatmi AMS, Arikan-Akdagli S, Badali H, Ben-Ami R, Bonifaz A, Bretagne S, Castagnola E, Chayakulkeeree M, Colombo AL, Corzo-León DE, Drgona L, Groll AH, Guinea J, Heussel CP, Ibrahim AS, Kanj SS, Klimko N, Lackner M, Lamoth F, Lanternier F, Lass-Floerl C, Lee DG, Lehrnbecher T, Lmimouni BE, Mares M, Maschmeyer G, Meis JF, Meletiadis J, Morrissey CO, Nucci M, Oladele R, Pagano L, Pasqualotto A, Patel A, Racil Z, Richardson M, Roilides E, Ruhnke M, Seyedmousavi S, Sidharthan N, Singh N, Sinko J, Skiada A, Slavin M, Soman R, Spellberg B, Steinbach W, Tan BH, Ullmann AJ, Vehreschild JJ, Vehreschild MJGT, Walsh TJ, White PL, Wiederhold NP, Zaoutis T, Chakrabarti A, Mucormycosis ECMM MSG Global Guideline Writing Group (2019) Global guideline for the diagnosis and management of mucormycosis: an initiative of the European Confederation of Medical Mycology in cooperation with the Mycoses Study Group Education and Research Consortium. The Lancet, Infectious disease 19(12):e405–21.

DGHS (2021) Guideline for management of mucormycosis in COVID-19 patients. Directorate General of Health Services, Ministry of Health & Family Welfare, Government of India. Available from: [Accessed 2021 Jul 17].

FISFTRUST (2022) Fungal Infection Study Forum, Available from: [Accessed 2021 Jul 17].

Georgiadou SP, Sipsas NV, Marom EM, Kontoyiannis DP (2011) The diagnostic value of halo and reversed halo signs for invasive mold infections in compromised hosts. Clinical infectious diseases 52(9):1144–1155.

Guinea J, Escribano P, Vena A, Muñoz P, Martínez-Jiménez M, Padilla B, Bouza E (2017) Increasing incidence of mucormycosis in a large Spanish hospital from 2007 to 2015: Epidemiology and microbiological characterization of the isolates. PloS one 12(6):e0179136.

Hiscott J, Alexandridi M, Muscolini M, Tassone E, Palermo E, Soultsioti M, Zevini A (2020) The global impact of the coronavirus pandemic. Cytokine & growth factor reviews 53:1–9.

Hoffmann K, Pawłowska J, Walther G, Wrzosek M, de Hoog GS, Benny GL, Kirk PM, Voigt K (2013) The family structure of the Mucorales: a synoptic revision based on comprehensive multigene-genealogies. Persoonia 30: 57–76.

Honavar SG (2021) Code Mucor: guidelines for the diagnosis, staging and management of rhino-orbitocerebral mucormycosis in the setting of COVID-19. Indian journal of ophthalmology 69(6):1361–5.

Ibrahim AS, Spellberg B, Walsh TJ, Kontoyiannis DP (2012) Pathogenesis of mucormycosis. Clinical infectious diseases 54(Suppl 1):S16–22.

ICMR (2021) Screening, diagnosis & management of mucormycosis: evidence based advisory in the time of COVID-19. Advisory Experts and National Task Force for COVID-19, Indian Council of Medical Research, Department of Health Research, Ministry of Health and Family Welfare, Government of India. Available from: [Accessed 2021 Jul 17].

Jeong W, Keighley C, Wolfe R, Lee WL, Slavin MA, Kong DCM, Chen SC (2019) The epidemiology and clinical manifestations of mucormycosis: a systematic review and meta-analysis of case reports. Clinical microbiology and infection 25(1):26–34.

John TM, Jacob CN, Kontoyiannis DP (2021) When uncontrolled diabetes mellitus and severe COVID-19 converge: the perfect storm for mucormycosis. Journal of fungi 7(4):298.

Kennedy KJ, Daveson K, Slavin MA, van Hal SJ, Sorrell TC, Lee A, Marriott DJ, Chapman B, Halliday CL, Hajkowicz K, Athan E, Bak N, Cheong E, Heath CH, Morrissey CO, Kidd S, Beresford R, Blyth C, Korman TM, Robinson JO, Meyer W, Chen SC, Australia and New Zealand Mycoses Interest Group of the Australasian Society for Infectious Diseases (2016) Mucormycosis in Australia: contemporary epidemiology and outcomes. Clinical microbiology and infection 22(9):775–781.

Kontoyiannis DP, Yang H, Song J, Kelkar SS, Yang X, Azie N, Harrington R, Fan A, Lee E, Spalding JR (2016) Prevalence, clinical and economic burden of mucormycosis-related hospitalizations in the United States: a retrospective study. BMC Infectious diseases 16(1):730.

Ministry of Health (2021) 29th meeting of group of ministers (GOM) on COVID-19. Available from: [Accessed 29 June 2021].

Nishanth G, Anitha N, Aravindha Babu N, Malathi L (2020) Mucormycosis - A review. European Journal of Molecular & Clinical Medicine 7(3):1786–1791.

Prakash H, Chakrabarti A (2019) Global epidemiology of mucormycosis. Journal of Fungi 5(1):26.

Prakash H, Ghosh AK, Rudramurthy SM, Singh P, Xess I, Savio J, Pamidimukkala U, Jillwin J, Varma S, Das A, Panda NK, Singh S, Bal A, Chakrabarti A (2019) A prospective multicenter study on mucormycosis in India: Epidemiology, diagnosis, and treatment. Medical mycology 57(4):395–402

Ragaller M, Richter T (2010) Acute lung injury and acute respiratory distress syndrome. Journal of emergencies, trauma, and shock 3(1):43–51.

Raut A, Huy NT (2021) Rising incidence of mucormycosis in patients with COVID-19: another challenge for India amidst the second wave? The Lancet, Respiratory Medicine

Reid G, Lynch JP III, Fishbein MC, Clark NM (2020) Mucormycosis. Seminars in respiratory and critical medicine 41(1):99–114

Revannavar SM, Supiya PS, Samaga L, Vineeth VK (2021) COVID-19 triggering mucormycosis in a susceptible patient: a new phenomenon in the developing world? BMJ case reports 14(4):e241663.

Rudramurthy SM, Hoenigl M, Meis JF, Cornely OA, Muthu V, Gangneux JP, Perfect J, Chakrabarti A (2021) ECMM and ISHAM. ECMM/ISHAM recommendations for clinical management of COVID-19 associated mucormycosis in low- and middle-income countries. Mycoses 64(9):1028–1037.

Singh AK, Singh R, Joshi SR, Misra A (2021) Mucormycosis in COVID-19: a systematic review of cases reported worldwide and in India. Diabetes & metabolic syndrome 15(4):102146.

Skiada A, Lass-Floerl C, Klimko N, Ibrahim A, Roilides E, Petrikkos G (2018) Challenges in the diagnosis and treatment of mucormycosis. Medical mycology 56(suppl 1):93–101.

Tamez-Pérez HE, Quintanilla-Flores DL, Rodríguez-Gutiérrez R, González-González JG, Tamez-Peña AL (2015) Steroid hyperglycemia: prevalence, early detection and therapeutic recommendations: a narrative review. World Journal of Diabetes 6(8):1073–81.

Webb BJ, Ferraro JP, Rea S, Kaufusi S, Goodman BE, Spalding J (2018) Epidemiology and clinical features of invasive fungal infection in a US health care network. Open Forum infectious diseases 5(8):ofy187.




How to Cite

Shaji, S. M. ., Krishnamoorthy, S. G. ., & Borra, S. S. (2022). Mucormycosis in COVID-19: modifiable risk factors and its mitigation in India. Italian Journal of Mycology, 51(1), 11–22.